A Phase 2/3 Open Label Randomized Study ofTelisotuzumab Adizutecan Compared to Standard of Care in Subjects with LocallyAdvanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung CancerAfter Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713